Immune interception represents an exciting opportunity to stop cancer in its tracks
Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions
Epigenetic information could harbour biomarkers of diagnosis and prognosis
Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment
A toolkit to address disparities in digitally enabled oncology trials
An initiative fosters inclusive research by improving patient access and participation in cancer research
AI and remote monitoring are shaping a new patient journey in oncology
Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting
Pan-cancer AI model shows to predict 30-day mortality in patients with advanced cancer
In a study, a machine learning approach outperformed cancer-specific models and revealed universal biomarkers to guide end-of-life care decisions
Data supports the use of an electric-based therapy combined to standard treatment in locally advanced pancreatic adenocarcinoma
Quality of life and pain management data adds to efficacy results of combining TTFields with gemcitabine and nab-paclitaxel as a potential new option of care
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Can AI help deliver better medicines to patients?
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain
ctDNA testing may help refine surveillance strategy for colorectal cancer
Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy